1-[4-(1-Hydroxypropan-2-yl)phenyl]-3-[[2-(4-methylpiperazin-1-yl)pyridin-3-yl]methyl]pyrrolidin-2-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 1-[4-(1-Hydroxypropan-2-yl)phenyl]-3-[[2-(4-methylpiperazin-1-yl)pyridin-3-yl]methyl]pyrrolidin-2-one
• 英文别名: 1-[4-(1-hydroxypropan-2-yl)phenyl]-3-[[2-(4-methylpiperazin-1-yl)pyridin-3-yl]methyl]pyrrolidin-2-one
• 化学式: C₂₄H₃₂N₄O₂
• 分子量: 408.5
• InChiKey: DIHKNBNYRZJCKN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  30
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  59.9
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• [EN] HTR1D INHIBITORS AND USES THEREOF IN THE TREATMENT OF CANCER<br/>[FR] INHIBITEURS DE HTR1D ET LEURS UTILISATIONS DANS LE TRAITEMENT DU CANCER
  申请人：INST CURIE

  公开号：WO2020183011A1

  公开（公告）日：2020-09-17

  The present invention deals with a 5 -hydroxytryptamine receptor 1D (5-HTR1D) inhibitor and with a combination of a 5-HTR1D inhibitor and at least one inhibitor of 5 -hydroxytryptamine receptor 1B (5-HTR1B) for use in the prevention and/or treatment of cancer in a subject in need thereof. According to the invention the cancer may be selected from the group comprising breast cancer, liver cancer, lung cancer, brain cancer, mesothelioma, head and neck squamous cell carcinoma, kidney cancer, gastric cancer and cervix cancer.